By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Incyte Corporation 

Experimental Station
Route 141 & Henry Clay Road, Building E336
Wilmington  Delaware  19880  U.S.A.
Phone: 302-498-6700 Fax: 302-425-2750


SEARCH JOBS








Company News
Incyte Corporation (INCY), Novartis AG (NVS)’ New Drug Helps Some Bald Patients Regrow Hair 8/18/2014 6:42:01 AM
Incyte Corporation (INCY) Release: FDA Accepts Supplemental New Drug Application For Jakafi® (Ruxolitinib) And Priority Review Granted 8/5/2014 10:03:59 AM
Incyte Corporation (INCY) Reports 2014 Second-Quarter Financial Results And Updates Shareholders On Key Clinical Programs 7/31/2014 10:39:45 AM
Incyte Corporation (INCY) Partners With Genentech (RHHBY) To Help With Cancer Immunotherapy Trials 7/30/2014 8:02:41 AM
Incyte Corporation (INCY) Release: Jakafi® (ruxolitinib) Product Label Expanded To Include Overall Survival Data And Additional Safety And Dosing Information 7/28/2014 8:49:58 AM
Incyte Corporation (INCY)'s Jakafi Fails to Provide RELIEF In Phase 3 Trial 7/24/2014 1:00:44 PM
Incyte Corporation (INCY) To Report Second Quarter 2014 Financial Results On July 31 7/14/2014 10:26:55 AM
Incyte Corporation (INCY) Grabs $25 Million Milestone From Novartis AG (NVS) 7/8/2014 10:02:31 AM
Incyte Corporation (INCY) To Present At The 9th Annual JMP Securities Healthcare Conference 6/12/2014 8:46:18 AM
Incyte Corporation (INCY) Release: Pivotal Phase 3 Data In Polycythemia Vera Show That Jakafi® (Ruxolitinib) Achieved Superior Disease Control Compared To Best Available Therapies 6/3/2014 10:06:43 AM
12345678910...
//-->